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Abstract
Autophagy has a crucial role in many cancers, including brain tumors. Several types of endogenous molecules (e.g.
microRNAs, AKT, PTEN, p53, EGFR, and NF1) can modulate the process of autophagy. Recently miRNAs (small non-
coding RNAs) have been found to play a vital role in the regulation of different cellular and molecular processes,
such as autophagy. Deregulation of these molecules is associated with the development and progression of
different pathological conditions, including brain tumors. It was found that miRNAs are epigenetic regulators, which
influence the level of proteins coded by the targeted mRNAs with any modification of the genetic sequences. It has
been revealed that various miRNAs (e.g., miR-7-1-3p, miR-340, miR-17, miR-30a, miR-224-3p, and miR-93), as
epigenetic regulators, can modulate autophagy pathways within brain tumors. A deeper understanding of the
underlying molecular targets of miRNAs, and their function in autophagy pathways could contribute to the
development of new treatment methods for patients with brain tumors. In this review, we summarize the various
miRNAs, which are involved in regulating autophagy in brain tumors. Moreover, we highlight the role of miRNAs in
autophagy-related pathways in different cancers.
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Background
Brain tumors arise from a wide variety of cell types,
which give rise to tumors with different degrees of
malignancy and invasiveness, and can afflict both adults
and children [1, 2]. Despite the low incidence of these
tumors, they are a leading cause of cancer-associated
mortality and morbidity, particularly in young adults and
children, where they account for about 20 and 30% of
cancer deaths, respectively. Metastasis to the central
nervous system (CNS) is also responsible for deaths in
patients with other types of malignancies. In 2015, CNS
tumors were estimated to represent 2.6% of cancer-
related deaths as well as 1.4% of newly diagnosed
cancers [3–5].
Because surgical brain tumor resection only leads to
survival of a few months (median of 3 months), many
studies have been done to improve the effectiveness of
treatment, because complete tumor removal is usually
impossible [6, 7]. The surgical elimination of the tumor
is dependent on the glioma sub-type and its location
within the brain [6]. However, although additional
chemotherapy and radiotherapy can prolong median
survival up to more than 1 year, tumor cells still develop
resistance mechanisms to these therapies [8–10]. Identi-
fying the detailed molecular mechanisms involved in
tumor progression could reveal novel approaches to
developing more effective therapies.
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Several studies have revealed the contribution of
autophagy in the pathogenesis of brain tumors [11, 12].
Autophagy is known to a well-conserved cellular path-
way designed for recycling and degrading damaged or
denatured proteins, together with long-lived or short-
lived intracellular organelles [13, 14]. The autophagy
process can be categorized into 3 sub-types called,
micro-autophagy, macroautophagy, and chaperone-
mediated autophagy [15]. Autophagy plays important
roles in many biological functions ranging from embry-
onic development to cellular survival [16]. Dysfunction
of the autophagic process has been correlated with a
wide range of age-related diseases, such as CNS-related
disorders and cancers [17]. In recent years, autophagy
has begun to be investigated as a therapeutic target in
several malignancies, such as breast cancer [18] and mel-
anoma [19, 20]. There are currently a few anticancer
treatments which act on autophagy pathways. Fortu-
nately, compounds that directly or indirectly modulate
autophagy are currently being studied in the context of
phase I and phase II clinical trials [21]. Additionally, the
regulation of autophagy has also been identified as an
approach to the treatment of brain tumors in both chil-
dren and adults [22–25].
Nevertheless, the precise role of autophagy in pediatric
CNS tumors is not completely understood, which high-
lights the need to reveal additional details of autophagy-
related processes to assess whether the contribution of
autophagy inhibition to cancer therapy is a valid ap-
proach [26]. It has been shown that various cellular and
molecular mechanisms are associated with autophagy-
related processes in brain tumors and also in other dif-
ferent cancers. Along with genetic mechanisms, epigen-
etic mechanisms (e.g., miRNA networks) play major
roles in the regulation of autophagy-related processes.
MicroRNAs (miRNAs) are short non-coding RNAs
that bind to the 3′ untranslated regions of messenger
RNAs (mRNAs) [27]. In fact, miRNAs can modulate the
expression of more than 50% of each gene because each
individual miRNA is able to target several different
mRNAs [28, 29]. Therefore, the deregulated expression
of miRNAs is likely to be related to the pathogenesis of
many malignancies, such as brain tumors [30]. A variety
of miRNAs are able to modulate autophagy, and its re-
lated mechanisms in various cancers including brain tu-
mors [31–35]. Taken together, many reports suggest
that a better understanding of the underlying molecular
mediators (i.e. miRNAs), and their functions in autoph-
agy pathways, could contribute to the discovery and ad-
vancement of novel treatment approaches for patients
with brain tumors. Some reviews explained the role of
miRNAs and autophagy in generally cancers [36, 37].
However until now, their specific roles in brain tumors
have not been described. Herein, for first time, we
summarize the various miRNAs which are involved in
regulating autophagy in brain tumors. Moreover, we
highlight the contribution of miRNAs to autophagy-
related mechanisms in different cancers.
Autophagy mechanisms
Autophagy (literally self-eating) is the conserved, regu-
lated mechanism for an orderly degradation and recyc-
ling of various cellular elements that are damaged or
unnecessary [38]. It is known that autophagy can be in-
duced in mammalian cells by different factors, such as
oxidative stress that leads to endoplasmic reticulum (ER)
stress. During ER stress, autophagy serves as an essential
protective response [39]. Autophagy was first fully inves-
tigated in yeast cells, and the terminolgy “autophagy
genes, ATG” was agreed upon to describe the proteins
involved. The two main regulatory pathways of the au-
tophagy machinery include the ATG5/7-independent
and ATG5/7-dependent pathways [40, 41].
According to the literature, the Unc-51-like kinase
(ULK) complex containing several proteins, such as
ATG101, ATG13, FIP200 (FAK-family interacting
protein of 200 kDa), as well as ULK1/2 (mammalian
ortholog of yeast ATG1) initiates conventional ATG5/7-
dependent autophagy [42, 43]. Under non-stressed con-
ditions, ULK1/2 is phosphorylated by the mammalian
target of the rapamycin complex 1 (mTORC1) resulting
in inactivation of the ULK complex [44]. On the other
hand, the nutrient-sensitive mTORC1 is inhibited under
nutrient-limiting conditions, and the ULK complex sub-
sequently remains non-phosphorylated, and is therefore
activated [45]. After activation, translocation of the ULK
complex to the phagophore, has been shown to occur.
After this, the class-III phosphatidylinositol 3-kinase
(PI3K) complex containing VPS34 (phosphatidylinositol
3-kinase Vps34), VPS15, Beclin1, as well as ATG14 pro-
teins, becomes activated [46]. This results in the forma-
tion of the mature autophagosome, after phagophore
closure and extension. Two different ubiquitin-like
conjugation systems, microtubule-related protein 1 light
chain 3 (LC3) and the ATG5-ATG12 system, are the key
modulators of the elongation and closure of the autophago-
somal membrane [47–49]. In addition, ATG7 (E1-like en-
zyme) can activate ATG12, which is then transported into
the ATG10 (E2-like enzyme) to eventually conjugate with
ATG5 in the ATG5-ATG12 pathway. The non-covalent
interaction of the ATG5-ATG12 complex with ATG16L
leads to the formation of a large multimeric (E3-like) com-
plex. This tripartite complex is capable of conjugating LC3
to phosphatidyl-ethanolamine (PE) to produce a LC3-PE
conjugate (which is called LC3-II). LC3-II is then loaded
into the phagophore [50–52]. In order to monitor the pro-
gression of autophagy, LC3-II protein is frequently
employed as a biomarker, since it is localized to both the
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outer and inner membranes of autophagosomes and
phagophores [53, 54].
Lysosomes, which are the degrading machinery in
autophagy, are related to MTORC1 activation via the
Rag/RRAG GTPase pathways. It has been shown that a
MTORC1 inhibitor could suppress lysosomal degrad-
ation and increase lysosomal permeability [55]. The
fusion of lysosomes with autophagosomes is the last step
in the autophagy degradation cascade, which is triggered
via three different sets of protein families: (a) RabGT-
Pases (Rab7 protein) [56, 57]; (b) HOPS (homotypic
fusion & the protein sorting tethering complex); and (c)
the SNAREs (soluble N-ethylmaleimide-sensitive agent
attachment protein receptors) [58–60]. Therefore, 3
distinct SNARE proteins; the vesicle-associated mem-
brane protein 8 (VAMP8); synaptosomal-associated pro-
tein 29 (SNAP29); and syntaxin 17 (STX17) can all
induce lysosome-autophagosome fusion [61, 62] (Fig. 1).
The mechanism of ATG5/7-independent autophagy
has been discussed by Nishida and colleagues (2009)
[43]. It was called “alternative autophagy” because ATG7
as well as ATG5 had been thought to be essential for au-
tophagy [43]. The important finding in their study was
that etoposide treatment of ATG5-deficient mouse em-
bryonic fibroblasts (MEFs) triggered autophagy to a
similar degree as in the wild type ATG5-expressing cells.
Additionally, researchers found that PI3K, beclin1, and
ULK1 complex played an important role, just as they do
in conventional autophagy. Moreover, it was also found
that silencing of the ATG5-ATG12 pathway had no ef-
fect on alternative autophagy, and that the conventional
lipidation of LC3 was carried out by Rab9 activity to
allow phagophore extension [43]. Rab9, which usually
induces protein transport from the late endosomes to
the trans-Golgi membrane, has been suggested to carry
out phagophore closure and extension in the alternative
Fig. 1 Autophagy mechanisms. Autophagy includes five steps: initiation, elongation, maturation, fusion and degradation. Various inhibitors can
affect on these processes
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autophagy pathway. This was the same process as
carried out by ATG5/ATG7/LC3 in the conventional
autophagy pathway [63–65]. There are multiple sources
of phagophores in the ATG5/7-dependent autophagy
pathway, but in the alternative autophagy pathway, the
trans-Golgi cisternae seem to be the origin of the mem-
branes [43, 66, 67].
Studies have shown that autophagy is a critical quality
control function in cellular processes. Autophagy at
baseline levels operates to sustain cellular hemostasis.
Some organelles undergo selective turnover through the
autophagy mechanism. Various autophagy pathways can
be distinguished by categorizing the contents of the
autophagosomes. These pathways include, lipid droplets
(lipophagy), ER (reticulophagy or ERphagy), secretory
granules (zymophagy), mitochondria (mitophagy), and
even some parts of the nucleus (nucleophagy). Further-
more, proteins that are prone to aggregation (aggre-
phagy), ribosomes (ribophagy), and pathogens
(xenophagy), can be specifically targeted and degraded
by autophagic processes [68]. Some types of autophagy
function as cellular quality control mechanisms. These
might be able to distinguish their substrates, including
dysfunctional mitochondria or protein aggregates from
their fully functional counterparts. Cargo selection, as
well as autophagy regulation, still have mechanistic as-
pects that remain to be discovered, and this has been a
focus of intense research interest in recent years. Re-
cently a genome-wide small interfering RNA screening
study was carried out to identify the various mammalian
genes that are necessary for selective autophagy. This
study discovered 141 candidate genes, of which 96 of
them were required for Parkin-mediated mitophagy [69].
It appears that these pathways involve particular cargo-
recognizing autophagy receptors that link the autophagic
membranes to the cargo. These receptors may also inter-
act with specific molecular adaptors, which act as scaf-
folding proteins. These proteins may help to connect the
cargo receptor complex to the core ATG machinery.
This connection allows selective sequestration of the
substrate. There are other types of autophagy that are
based on similar core molecular machinery to the non-
selective (starvation-induced) bulk autophagy. On the
contrary, specific molecular adapters or autophagy
receptors are not necessary for the non-selective autoph-
agy pathway. Autophagy receptors have been proposed
as being capable of directing interaction with ATG8/
LC3 family members, as well as the autophagosome
cargo via specific (WxxL) sequences [70]. These are usu-
ally referred to as LC3 recognition sequences (LRS) or
LC3-interacting region (LIR) motifs [71, 72]. By compar-
ing the LIR domains among 20 different autophagy
receptors, studies found that the LIR consensus recogni-
tion motif comprised a sequence of 8 amino acids. This
sequence can be written down as D/E-D/E-D/E-W/F/Y-
X-X-L/I/V. This is not, however, an essential condition,
because at least one acidic residue upstream of the W-
site exists. On the other hand, the terminal L-site con-
tained a hydrophobic aminoacid residue, L, V, or I [73].
It was found that the LIR motifs of numerous autophagy
receptors could all interact with both GABARAP and
LC3 family members in vitro. But whether this inter-
action actually occurs under physiological conditions
should be elucidated in most cases. It may be the case
that all the LIR-containing proteins are not necessarily
autophagy-cargo receptors. For example, there are a
number of LIR proteins, such as ATG4B as well as
ATG3, which could function in the autophagic mem-
brane to produce autophagosomes [74, 75]. Other pro-
teins, such as the coiled-coil domain-containing protein
1 (FYCO1) and FYVE can interact with LC3 to promote
autophagosome maturation [76]. Other proteins, includ-
ing Dishevelled, act as adaptors in the Wnt signaling
pathway, and may exploit an LIR motif for their degrad-
ation [77]. These adaptor proteins have not yet been
completely described, but they appear to interact with
autophagy receptors and act as scaffold proteins for the
assembly of the ATG machinery. This allows the pro-
duction of autophagosomes that surround the cargo that
is required to be degraded. ATG11 and ALFY are exam-
ples of these autophagy adaptors [78, 79]. The
cytoplasm-to-vacuole targeting (Cvt) pathway mediates
the transportation of some vacuolar hydrolases, such as
amino-peptidase 4 (Ape4), α-mannosidase (Ams1), ami-
nopeptidase 1 (Ape1), and Ty1 transposon (in yeast) into
the vacuole [80, 81]. Ape1 is generated from a cytosolic
precursor (prApe1), which undergoes multimerization
into higher order Ape1 oligomers. Ams1, Ty1, and Ape4
then associate with the Ape1 oligomer to generate the
fully assembled Cvt complex, which is sequestered in a
small autophagosome-like vesicle. Sequestering the Cvt
complex inside the Cvt vesicle is a multistage process,
requiring the autophagy receptor ATG19 that promotes
ATG8 binding to PAS, and to adaptor protein ATG11
(Fig. 2a) [82]. ATG11 functions as a scaffold protein by
controlling the ATG9 reservoir, and allowing the Cvt
complex to bind to PAS in an actin-dependent manner,
and consequently forming the ATG1/ULK complex [83].
ATG20, ATG21, and ATG24 are PI3P-binding proteins,
which have been found to be necessary for the Cvt func-
tion, however, the exact functions of these proteins is
not yet clear. Surprisingly, over-expression of ATG11
led to greater ATG9 and ATG8 binding to PAS and
more Cvt vesicles [84]. These results suggest that the
level of ATG11 can selectively control the autophagy
rate. ATG11 can also control the size of the cargo-
loaded autophagosomes in yeast [85]. Some studies have
shown that ATG11 can contribute to other types of
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selective autophagy, including pexophagy and mito-
phagy. The individual autophagy receptors participating
in different ATG11-dependent types of selective autoph-
agy vary, because ATG32 is necessary for mitophagy,
while ATG30 is required for pexophagy [86, 87]. There-
fore, these receptors possess an ATG8-binding LIR motif
similar to ATG19, that governs the interaction with
ATG11. It seems that mammalian cells do not have the
ATG11 homologue. More investigations are required to
define the molecular mechanisms that govern the se-
questering as well as targeting the various cargoes to be
broken down by autophagy in different eukaryotes. The
Cvt pathway machinery appears to be similar to the
mammalian autophagy, named aggrephagy. This entails
the degradation of misfolded and unwanted proteins via
assembling them into ubiquitinated aggregates. Thus,
aggregation of the substrates (prApe1 or misfolded pro-
teins) is essential before sequestering them into the Cvt
vesicles or autophagosomes [88]. Aggregate-containing
autophagosomes, similar to Cvt vesicles, seem to not
contain any cytosolic elements, demonstrating the well-
controlled expansion of the vesicle membrane surround-
ing its cargo [78]. Besides, aggrephagy is dependent on
the unique functions of proteins that select the substrate
[89]. The p62 autophagy receptor and adjacent BRCA1
gene (NBR1) bind the ubiquitinated protein aggregates
via an ubiquitin-associated (UBA) domain, as well as
LC3, through their LIR motifs. This process ensures the
selective autophagic breakdown of the ubiquitinated pro-
teins (Fig. 2b) [90].
p62 and NBR1 also include a Bem1p (PB1) domain
and an N-terminal Phox by which they can be
Fig. 2 Mechanisms for selective autophagy. a Targeting pathway from the cytoplasm to the vacuole (Cvt). Ape1 is generated as a cytoplasmic
precursor protein alongside a propeptide. The molecule will rapidly oligomerize into dodecamers. These dodecamers will link to each other to
create higher-order composites. ATG19 as an autophagy receptor directly attaches to this complex and leads to another Cvt pathway cargo
named Ams1 resulting in the formation of the Cvt complex and ATG19 interaction with an autophagy adaptor ATG11. The Cvt complex is
transported to the location wherein the double-membrane vesicle will be created. ATG11 binds the ATG proteins required to generate Cvt
vesicles. However, ATG19 direct binding to ATG8 allows unique sequestration of the Cvt complex into vesicles. b Scheme for p62 as well as NBR1
acting as autophagy receptors along with the ubiquitinated cargos. Furthermore, P62 and also NBR1 bind to the ubiquitinated cargo through
their ubiquitin-associated (UBA) domain. This interaction initiates aggregate generation via oligomerization of p62 through its Bem1p (PB1) and
Phox domains. p62 interacts with autophagy-linked FYVE protein (ALFY) to activate ATG5 and bind PI3P, as well as direct binding to LC3. These
mechanisms seem to control and activate the ATG function along with the ubiquitinated cargos, and specifically sequester them inside
autophagosomes, similar to the Cvt pathway
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oligomerized, or interact with PB1-containing binding
partners [73]. Moreover, p62 has been implicated as a
cargo receptor for protein aggregates in the autophagic
breakdown of additional ubiquitinated substrates. These
substrates include viral capsid proteins, intracellular bac-
teria, peroxisomes, midbody remnants formed after cyto-
kinesis, bactericidal precursor proteins, and damaged
mitochondria [91]. It has been recently found that the
PB1 domain was necessary for p62 to restrict the autop-
hagosome genesis site in the vicinity of the ER. It was
suggested that PB1 may target the ubiquitinated cargos
to the location of autophagosome formation, or alterna-
tively to improve the assembly of ATG complexes at the
site [91].
MicroRNA biogenesis
MicroRNAs are non-coding single-stranded RNA mole-
cules with a length of approximately 17–25 nt. These
molecules modulate biological processes by posttran-
scriptional gene silencing [92]. Necrotic cells are able to
release the miRNAs as naked oligonucleotides, or else
they are secreted contained in extracellular vesicles. Fur-
thermore, researchers have detected circulating miRNAs
(c-miRNAs) in many body fluids, such as cerebrospinal
fluid (CSF). It has been proposed that these c-miRNAs
play a role in intercellular communication, and thus can
possibly affect various cellular processes at a molecular
level, such as cell growth and invasiveness, and can also
affect drug resistance in the recipient target cells [93,
94].
Long primary pri-miRNAs or miRNAs are usually
transcribed from miRNA genes by RNA polymerase II
[95]. Pri-miRNAs may occasionally produce several dif-
ferent functional miRNAs [95]. In order to produce
hairpin-structured pre-miRNAs, a core ribonuclease
complex, such as Drosha or the respective modulatory
sub-unit DGCR8 is used to process them in the nucleus.
Following cleavage, these hairpin-structured premiRNAs
are transferred from the nucleus into the cytoplasm.
Moreover, further cleavage of the pre-miRNA hairpin
structure in the cytoplasm is carried out by DICER pro-
tein, resulting in the formation of long miRNA duplexes.
These duplexes are loaded into the RNA-induced silen-
cing complex (RISC). In addition, Argonaute (AGO)
proteins are essential elements of the RISC that direct
mature single-stranded miRNAs to their target mRNAs.
However, the destiny of the targeted mRNA is governed
by the interrelationship between the miRNA response el-
ements (MRE) and the mature miRNA seed sequences.
Therefore, base-pairing of the target mRNA to the guide
miRNA leads to its endonuclease-mediated cleavage in a
slicer-dependent manner. The degradation process can
be proceeded by miRNA-mediated deadenylation and/or
de-capping of the target mRNA, while the translation
machinery may be blocked by partial complementary
binding (Fig. 3) [96, 97].
Regulation of autophagy by microRNAs in cancer
Over the past decade, it has been found that miRNAs
are able to control a number of ATGs (and their re-
spective modulators) at various steps of the autophagy
process, including vesicle nucleation, induction, retrieval,
fusion, and finally vesicle elongation (Fig. 3) [98]. The
first step in the induction of autophagy is triggered by
ULK complex activation. This complex includes the
components, ULK1/2, FIP200, and FIP200 [98, 99].
Moreover, ULK1 protein kinase has been considered to
be the main initiator of the autophagic process. In
nutrient-rich conditions, mTOR is able to phosphorylate
the mammalian ATG13 (mATG13) and ULK1 that to-
gether prevent the activation of ULK1 kinase. However,
under starvation conditions, mTOR is inactivated which
then allows ULK1 to phosphorylate FIP200 and
mATG13 as well as itself. This leads to engagement of
ATG complexes, like class-III phosphatidylinositol 3-
kinase (PI3KCIII) to initiate autophagy. In addition, the
miR-290–295 cluster was shown to down-regulate ULK1
levels, so that ATG7 inhibited autophagic cell death
caused by glucose starvation [100]. Leucine deprivation
also repressed expression of miR-106b and miR-20a
through repression of the transcription factor c-Myc.
Transfection of miR-20a or miR-106b mimics could
hamper the leucine deprivation mediated autophagy in
C2C12 myoblasts. This mechanistic investigation sug-
gested the probable targeting of ULK1 by miR-106b and
miR-20a, as well as directly preventing its expression
[101]. A simple chalcone-type flavonoid compound,
called isoliquiritigenin can be isolated from liquorice
compounds. This flavonoid mediated cell cycle arrest,
chemo-sensitization, as well as autophagy in multidrug
resistant MCF7 cells. This mechanic investigation sug-
gested that miR-25 was a key target of soliquiritigenin.
Moreover, miR-25 suppression caused autophagic cell
death via direct ULK1 over-expression [102].
It was reported that miR-126 was down-regulated in
malignant mesothelioma tissue, and also that its over-
expression inhibited cancer cell growth, probably be-
cause of its impact on their metabolism. miR-126 also
led to energy deprivation, reduced glucose uptake, and
inhibited IRS1, resulting in ULK1 activation [103]. Fur-
thermore, miR-126 also affected other metabolism-
associated proteins, including acetyl-CoA-citrate and
pyruvate dehydrogenase kinase. These metabolic
changes induced by miR-126 resulted in the suppression
of tumor growth and activation of autophagy both
in vitro and in vivo [103].
It was recently reported that ULK2, which is another
up-stream autophagy initiator, is a direct target of miR-
Pourhanifeh et al. Cell Communication and Signaling           (2020) 18:88 Page 6 of 22
885-3p. Therefore, miR-885-3p may be involved in
autophagy modulation [104]. Vesicle nucleation was
induced by activation of the class-III PI3K/Beclin-1
complex. This complex has numerous binding partners,
including hVPS34, UV-irradiation resistance-associated
gene (UVRAG), Bax-interacting factor-1 (BIF-1), ATG14L,
and Rubicon. Several miRNAs, including miR-376b, miR-
30a/b, miR-17-5p, and miR-216a can all hamper Beclin-1
expression, and inhibit vesicle nucleation [105–108]. In
one study Huang et al. showed that miR-519a could dir-
ectly target Beclin-1 [109]. Furthermore, it was shown that
miR-374a (as well as miR-630) could inhibit the inter-
action of UVRAG with Beclin-1, resulting in autophagy
activation. ATG14 is a vital component of the class III
PI3K/Beclin-1 complex in the nucleation of autophagoso-
mal membranes. ATG14 has also been recognized as a
miR-195 target [110]. Moreover, RAB5A a small GTPase,
which interacts with Beclin-1 and hVPS34 is able to medi-
ate autophagosome formation. In addition, RAB5A can
also be targeted by miRNA-101 to inhibit autophagy,
showing that miR-101 can regulate autophagy at the
vesicle nucleation stage [111, 112]. Thirdly, two different
ubiquitin-like conjugation mechanisms can act to elongate
the vesicle: one is the ATG8-phosphatidyl ethanolamine
mechanism and the other is ATG12-ATG5-ATG16L. Sev-
eral proteins are involved in this process, including ATG7,
ATG10, ATG4, ATG5, ATG3, ATG12, ATG16L, as well
as microtubule-related protein 1 light chain 3 (LC3). MiR-
376b and miR-101 can negatively modulate ATG4C and
ATG4D expression [107, 112]. MiR-376a was found to
have a similar seed sequence and similar targets to miR-
376b, including Beclin-1 [113] and ATG4C (90).
In hepatocellular carcinoma (HCC) cells, the conver-
sion of LC3-I into LC3-II is inhibited by miR-375 via
targeting of ATG7 [114]. Besides, miR-17 could also de-
crease the expression of ATG7 in glioblastoma cell lines
[115]. Furthermore, RAB5A participates in the conjuga-
tion of ATG5 to ATG12 [112]. Thus, miR-101 by target-
ing RAB5A, could have an impact on both the
nucleation and elongation of the vesicles. In addition,
Fig. 3 MicroRNA processing and function. In order to produce hairpin-structured pre-miRNAs, a core ribonuclease complex, such as Drosha or
the respective modulatory sub-unit DGCR8 is used to process them in the nucleus. Following cleavage, these hairpin-structured premiRNAs are
transferred from the nucleus into the cytoplasm. Moreover, further cleavage of the pre-miRNA hairpin structure in the cytoplasm is carried out by
DICER protein, resulting in the formation of long miRNA duplexes. These duplexes are loaded into the RNA-induced silencing complex (RISC). In
addition, Argonaute (AGO) proteins are essential elements of the RISC that direct mature single-stranded miRNAs to their target mRNAs. However,
the destiny of the targeted mRNA is governed by the interrelationship between the miRNA response elements (MRE) and the mature miRNA
seed sequences. Therefore, base-pairing of the target mRNA to the guide miRNA leads to its endonuclease-mediated cleavage in a
slicer-dependent manner
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miR-204 was able to modulate autophagy in renal clear
cell carcinoma (RCC) by modulating LC3B [116].
MiR142-3p, miR-106B, and miR-93 can all stimulate
autophagy by targeting ATG16L [117, 118]. Whereas,
miR-519a, miR-130a, miR-30a/c, miR-885-3p, miR-630,
miR-181a, and miR-374a, can repress autophagy by tar-
geting ATG5-ATG12 conjugation [119, 120]. The fusion
and retrieval process of autophagosomes could be mod-
ulated by targeting UVRAG, ATG9, ATG18, as well as
ATG2. Many different miRNAs can participate in this
final stage of autophagy. Moreover, ATG2B has been
established as one of the direct targets of miR-130a
[121]. Thus, MiR-34 suppresses autophagy via decreas-
ing ATG9 expression in mammalian cells [122]. Jegga
et al. investigated the transcriptional as well as the post-
transcriptional modulation of ATGs mediated by miR-
NAs. They showed that miR-130, 124, 98, 142, and 204
were all involved in the modulation of autophagy-
lysosomal pathway genes. UVRAG is also one of the key
molecules in the fusion process. The miRNAs that target
UVRAG including miR-374a as well as miR-630, may
participate in the modulation of autophagosome–lyso-
some fusion [109]. There are also some other miRNAs
that could be involved in autophagy modulation. BCL-2
binds to Beclin-1, and consequently inhibits Beclin-1-
dependent autophagy. MiR-182, miR-34a, miR-210,
miR-21, and miR-205 can target BCL-2, and are likely to
modulate autophagy via the BCL-2/Beclin-1-PI3KIII
pathways [123–126]. The p62 protein, called sequesto-
some 1 (SQSTM1), is a selective substrate for autophagy,
and also acts a scaffold in the autophagosome. The miR-
17/20/93/106 has a common AAGUGC seed motif, and
can directly modulate the expression of p62, suggesting
a possible role in autophagy modulation [126]. The
hypoxia-induced miR-155 can promote autophagy by
targeting numerous genes in mTOR signaling pathways,
such as RICTOR, RPS6KB2, as well as RHEB [127]. Fur-
thermore, miR-100 is able to enhance autophagy in he-
patocellular carcinoma cells via targeting IGF-1R as well
as mTOR [128]. Histone deacetylases (HDACs) and his-
tone acetyltransferases (HATs) have a key role in epigen-
etic regulation by affecting protein acetylation. MiR-9
and miR-206 can modulate HDAC and HAT expression
in Waldenstrom macroglobulinemia (WM) cells, leading
to autophagy dependent cell death [129]. HDAC6 is a
prominent cytoplasmic deacetylase, that targets heat
shock protein 90, cortactin, and tubulin. Thus, HDAC6
can modulate cell motility, adhesion, and chaperone
function [130]. It has been shown that HDAC6 has a
role in carcinogenic transformation and may regulate
the epithelial-mesenchymal transition (EMT) in various
types of cancer via modulation of major cellular compo-
nents. Many pieces of evidence suggest that HDAC6
expression is correlated with tumor aggressiveness,
anchorage-independent proliferation, and oncogenic
transformation [131, 132]. Studies have shown that
HDAC6 has a role in the clearance of aggresomes. These
studies also pointed out a functional connection between
autophagy and HDAC6 [133]. Another study showed that
transfection with miR-221 mimics could inhibit HDAC6
expression in pancreatic cancer cells compared to negative
controls [133]. In pancreatic cancer cells, the suppression
of HDAC6 could mediate autophagy. Down-regulation of
miR-221 expression via increasing HDAC6 function could
play an oncogenic role in suppressing autophagy and
apoptosis in pancreatic cancer cells [133].
Long non-coding RNAs are another member of the
class of non-coding RNAs that could have a crucial role
in cancer pathogenesis [134]. It is thought that lncRNAs
exert their modulating roles via sponging of miRNAs
and proteins. The physiological and biological roles of
autophagy-regulating lncRNAs in cancer have recently
been appreciated. The expression of lncRNAs substan-
tially affects the level of autophagy at various steps of
carcinogenesis, and especially in advanced metastatic
cancer [134]. It has been proposed that impaired expres-
sion of MALAT1 (metastasis associated lung adenocar-
cinoma transcript 1) regulates autophagy in different
cancers such as RTB, HCC, glioma, and GC via modula-
tion of miRNAs, miR-101, miR-124, miR-23b-3p, as well
as miR-216b [135–138]. Autophagy and GAS5 expres-
sion were both decreased in breast cancer cells. Further-
more, the GAS5 expression levels in patient samples
showed a negative correlation with tumor size, depth,
TNM stage, as well as with poor clinical prognosis. Sur-
prisingly, vector-induced GAS5 over-expression initiated
autophagy, and also elevated p62, LC3, and ATG3 ex-
pression through sponging of miR-23a. This result could
be helpful as a novel treatment for breast cancer via
modulating the GAS5/miR-23a/ATG3 axis [139].
RNA editing involves discrete changes being made to
specific nucleotide sequences within an existing RNA
molecule. It has recently been shown that the process of
A-to-I RNA editing can alter miRNA function [140]. For
instance, compared to the wild-type miRNA, the edited
miR-200b could increase the invasion and migration of
cancer cells [141]. In another study, it was shown that the
edited miR-379-5p, as opposed to the wild-type miR-379-
5p that targets CD97, suppressed rapid cell proliferation
and increased apoptosis in tumor cells in-vitro [142].
Table 1 and Fig. 4 lists various autophagy-related miRNAs
that have been reported to be involved in cancer.
Autophagy and brain tumors: paving the way for
the development of new drugs
Alterations in autophagy in brain tumors
The poor response of malignant brain tumors to con-
ventional therapies, many of which work by inducing
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Table 1 Selected autophagy-associated miRNAs in cancer
Cancer MicroRNA Target (s) Effect (s) Cell line (s) Ref
Melanoma miR-290-295 ATG7, ULK1 Inhibit autophagy R2L, B16F1 [100]
miR-638 TP53INP2 Inhibit autophagy SK-Mel-147, SK-Mel-28 [143]
Esophageal cancer miR-193b STMN1 Activate autophagy KYSE450 [144]
miR-634 BIRC5, XIAP, APIP, TFAM, OPA1, LAMP2 Inhibit autophagy KYSE850 [145]
Squamous cell carcinoma miR-374a ATG5, UVRAG Inhibit autophagy JHU-029 [146]
miR-630 UVRAG, ATG12 Inhibit autophagy JHU-029 [146]
miR-519a BECN1, ATG16L1, ATG10 Inhibit autophagy JHU-029 [146]
miR-885-3p AKT1, ULK2, ATG16L2, BCL-2 Inhibit autophagy JHU-029 [147]
Colorectal cancer miR-18a hnRNPA1 – HCT116, SW620 [148]
miR-22 BTG1 Inhibit autophagy RKO, SW620 [149]
miR-93 ATG16L1 Inhibit autophagy HCT116 [150]
miR-106 ATG16L1 Inhibit autophagy HCT116 [150]
miR-183 UVRAG Inhibit autophagy HT29, HCT116 [151]
miR-409-3p BECN1 Inhibit autophagy LovoOxa R [152]
miR-502 RAB1B Inhibit autophagy HCT116 [153]
Gastric cancer miR-143 GABARAPL1 Inhibit autophagy MKN28, AGS [154]
miR-181a ATG5 Inhibit autophagy SGC7901/CDDP [155]
Lung cancer miR-7 EGFR Activate autophagy A549, H1299 [156]
miR-16 BCL-2 Inhibit autophagy A549-T24 [157]
miR-17-5p BECN1 Inhibit autophagy A549-T24 [105]
miR-143 ATG2B Inhibit autophagy H1299 [158]
miR-144 TIGAR Activate autophagy H460, A549 [159]
miR-200b ATG12 Inhibit autophagy H1299/DTX, SPC-A1/DTX [160]
miR-216b BECN1 Inhibit autophagy Calu-3, A549 [161]
miR-451 RAB14 – A549, NCI-H520, SPC-A1 [162]
miR-487b-5p LAMP2 Inhibit autophagy H1299, A549 [163]
Breast cancer miR-25 ULK1 Inhibit autophagy MCF-7 [102]
miR-181a ATG5 Inhibit autophagy MCF-7 [119]
miR-199A-5p BECN1, DRAM1 Inhibit autophagy MDA-MB-231, MCF-7 [164]
miR-200c UBQLN1 Activate autophagy MDA-MB-231 [165]
miR-372 SQSTM1 Inhibit autophagy MCF10A, MCF-7 [166]
miR-376b ATG4C, BECN1 Inhibit autophagy MCF-7 [113]
miR-451a – Inhibit autophagy LCC2, MCF-7 [167]
Ovarian cancer miR-152 ATG14 Inhibit autophagy SKOV3/DDP, A2780/CP70 [168]
miR-373 RAB22A Inhibit autophagy SKOV3 [169]
Cervical cancer miR-15a/16 RICTOR Activate autophagy HeLa [170]
miR-20a ATG7 – SiHa [171]
miR-155 RHEB, RPS6KB2, RICTOR Activate autophagy HeLa, NSE [127]
miR-224-3p FIP200 Inhibit autophagy SiHa, HeLa, C33A [172]
Endometrial carcinoma miR-218 HMGB1 Inhibit autophagy RL95–2 [173]
Prostate cancer miR-96 ATG7, mTOR Inhibit autophagy LAPC4, 22Rv1, LNCaP [174]
miR-124 PIM1 Inhibit autophagy PC3, DU145 [175]
Liver cancer miR-21 PTEN Inhibit autophagy HepG2, Huh7 [176]
miR-101 EZH2 Inhibit autophagy HepG2 [177]
Pourhanifeh et al. Cell Communication and Signaling           (2020) 18:88 Page 9 of 22
apoptosis, makes it attractive to target autophagy as an
alternative mechanism for triggering glioma cell death
[185, 186]. Alterations or mutations that are commonly
found in brain tumors, include p53, PTEN, AKT, NF1
and EGFR, and some of these are accepted to be impli-
cated in the modulation of autophagy [185, 186]. Con-
sidering the frequencies of mutations in EGFR, p53,
PTEN, NF1, and PDGFR, the Cancer Genome Atlas con-
sortium categorized glioblastoma (GBM) tumors into
four molecular sub-types, including neural, classical,
mesenchymal, and proneural [187]. Researchers have
also found differences in basal expression levels of the
LC3 protein in xenografts of the GBM four subtypes,
which were associated with differences in the
Table 1 Selected autophagy-associated miRNAs in cancer (Continued)
Cancer MicroRNA Target (s) Effect (s) Cell line (s) Ref
miR-199A-5p ATG7 Inhibit autophagy HepG2, Huh7 [178]
miR-224 SMAD4 Inhibit autophagy Hbx, Hep3B [179]
miR-375 ATG7 Inhibit autophagy Hep3B, Huh7 [114]
miR-376b ATG4C, BECN1 Inhibit autophagy Huh7 [113]
Pancreatic cancer miR-23a ATG12 Inhibit autophagy BxPC3 [180]
miR-216a BECN1 Inhibit autophagy PANC-1 [181]
Kidney cancer miR-214 LC3B, LC3A Inhibit autophagy A498, 786-O, Caki-1 [182]
Thyroid cancer miR-9-3p ATG5 Inhibit autophagy MZ-CRC-1, TT [183]
Hepatocellular carcinoma miR-17 PTENP1, PTEN Activate autophagy Mahlavu [184]
miR-19b PTENP1, PTEN Activate autophagy Mahlavu [184]
miR-20a PTENP1, PTEN Activate autophagy Mahlavu [184]
Fig. 4 Various microRNAs involved in autophagy-related mechanisms. MiR-31, miR-34a miR-9 and miR-101 are able to affect on degradation and
recycling. MiR-204, miR-183, 101, and miR-376b affect on Autophagosome
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susceptibility to autophagy. It has been proposed that
combinational approaches targeting autophagy-
lysosomal related mechanisms might result in improved
GBM subtype-specific treatments. Furthermore, it has
been shown that autophagy can be activated by some ex-
perimental glioma treatments. Although autophagy
can increase the survival and resistance of tumor cells
under some circumstances, autophagy is also able to
exert cytostatic and/or cytotoxic effects in other
therapeutic approaches. The particular role of autoph-
agy in contributing to cell death or cell survival in
different therapeutic approaches is yet to be fully ex-
plained, and a better understanding of these contrary
findings is essential to design potential combination
therapies [187].
The most frequent genetic alterations/mutations found
in gliomas are: hemizygous/homozygous deletion of NF-
1 and PTEN; EGFR vIII mutant expression; and EGFR
amplification [187]. The abnormal signaling resulting
from such mutations interacts with PI3K-Akt-mTOR
pathways that promotes chemo-resistance and survival
in gliomas [188]. Thus, the idea to target receptor tyro-
sine kinases (RTKs) using small molecule inhibitors, or
else with monoclonal antibodies has emerged as a fa-
vored therapeutic approach (Fig. 5).
Development of therapeutic drugs
Disappointingly, the first clinical trials that were con-
ducted with small molecule EGFR inhibitors, including
gefitinib and erlotinib that had shown success for other
tumor types, did not show any encouraging results for
glioma treatment [189–191]. Likewise, monoclonal anti-
bodies targeting EGFR (panitumumab and cetuximab)
only exerted cytostatic effects on glioma cell lines [192,
193]. However, the variety of different types of RTK that
are found in gliomas (combined with frequency of PTEN
elimination) could explain the ineffectiveness of tyrosine
kinase inhibitors (TKI) each of which only targets a sin-
gle enzyme [194–196]. Moreover, preclinical investiga-
tions using selected mTOR and PI3K inhibitors, have
shown only a moderate efficacy against gliomas. A
phase-II trial using temsirolimus (CCI-779), a mTOR
blocker, did not improve survival in patients with recur-
rent GBM [197]. However, PI-103, a dual functional
mTOR and PI3K inhibitor, did show beneficial anti-
proliferative effects in preclinical glioma models, by sup-
pressing the Akt activation often found with mTOR
blockers [198]. Treatments which targeted components
of the RTK-PI3K-Akt-mTOR axis, increased the induc-
tion of autophagy with an overall cytoprotective effect.
Therefore, a combination of inhibitors of late stage au-
tophagy plus other compounds that actually induce au-
tophagy may work together to increase the cytotoxicity
in gliomas. Indeed, this concept was tested in one
approach, which combined the lysosomotrophic agent
chloroquine (CQ) that blocked the activity of lysosomal
proteases, with the PI3K/mTOR/AKT inhibitors (AKT-
1/2 and PI-103), resulting in the overall potentiation of
glioma cell death [199]. Furthermore, NVP-BEZ235 (a
dual mTOR and PI3K inhibitor currently being tested in
clinical trials) induced autophagy in solid tumors, and
synergistically acted in combination with CQ through
increased apoptosis in glioma cells [200]. A combination
of monensin or bafilomycin A1 (both late-stage autoph-
agy inhibitors) with Ku-0063794 or PI-103 also pro-
moted glioma cell death via apoptosis induction [200].
Also, experts in the field have proposed that inhibition
of autophagy could act synergistically with erlotinib for
induction of cytotoxicity in GBM cells [201]. In the case
of a combination of autophagy inhibitors with the TKI,
imatinib mesylate, the precise stage at which autophagy
was suppressed led to different outcomes in gliomas.
Early-stage inhibition of autophagy using small interfer-
ing RNAs targeting ATG5 or 3-methyladenine (3-MA)
decreased imatinib cytotoxicity, whereas conversely sup-
pression of late-phase autophagy using bafilomycin A1
increased cytotoxicity by inducing more apoptosis [202].
Therefore, the varying outcomes of autophagy suppres-
sion under different conditions may depend on the spe-
cific compound that targets different stages of
autophagy, and on other factors that are not yet com-
pletely understood.
Although the combination of drugs which induce
autophagy, with agents that inhibit the completion of
autophagy, appear to be somewhat promising up to
now, and some clinical trials are actually in progress,
there are other treatments that can contribute to
autophagy-associated glioma cell death. For example,
adding an inducer of autophagy, to some common
chemotherapeutic drug regimens could increase
cytotoxicity.
Several agents can cause autophagic cell death in dif-
ferent kinds of cancer, such as IFN-γ, resveratrol, vita-
min D analogues, tamoxifen, arsenic trioxide, and
actinomycin D. In glioma cell lines, it has been shown
that arsenic trioxide can induce autophagy-related cell
death by up-regulation of BNIP3 (a member of the Bcl-2
family), as well as its respective homologue BNIP3L. Ac-
cording to earlier findings, displacement of Beclin1 from
its complex with Bcl-2 (BNIP3) enhances autophagy.
Furthermore, BNIP3 over-expression also induced au-
tophagy in some cell types [203]. Likewise, BNIP3 can
make a key contribution to ceramide-mediated autoph-
agy in malignant glioma cells [204]. An inorganic com-
pound, sodium selenite, was also able to induce
autophagy in malignant glioma cells via superoxide-
induced mitochondrial damage [205]. Sodium selenite,
ceramide and arsenic trioxide have all been shown to
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contribute to autophagic cell death by triggering mito-
chondrial damage. However, Δ9-tetrahydrocannabinol
(THC) resulted in autophagy-related glioma cell death
through induction of ER stress [206].
GBMs contain many hypoxic regions, and there can
also be large necrotic regions inside the tumors. In-
creased expression levels of Bcl-2 family members leads
to resistance to hypoxia in gliomas [207], and may result
in increased resistance to some therapies. BH3 mimetics
are small molecules, which can selectively attach to the
BH3-binding groove of the anti-apoptotic Bcl-2 proteins.
Therefore, BH3 mimetics are able to disturb the inter-
action between Bcl-2/beclin1 as well as between Bax/
Bcl-2, in order to trigger autophagy or apoptosis in dif-
ferent kinds of cancer. In hypoxia-resistant malignant
glioma cells, it was found that BH3 mimetics could in-
duce autophagy-dependent cell death [207]. In addition,
gossypol (a BH3 mimetic) specifically induces caspase-
independent autophagic cell death [208].
p53 has been shown to be mutated in about one third
of gliomas, and it can reduce the susceptibility of tumors
to treatments that induce apoptosis [209]. Investigators
have found that autophagy-related cell death can be in-
duced in gliomas by addition of CQ, independently of
the p53 status [210]. Nevertheless, p53 plays an essential
role in governing autophagy in a variety of therapeutic
approaches. Autophagy and DNA damage have both
been induced by selective inhibitors of cyclooxygenase-2
(e.g. celecoxib) in glioma cells, which require a func-
tional p53 pathway [211].
Fig. 5 Autophagy in brain tumors and possible role of inhibitors in brain tumor treatment. Various inhibitors exert their effect on different targets
in glioma cells. Dual inhibitors (PI-103 and NVP-BEZ235) inhibit mTOR. TKI inhibits RTK and PI3K
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MicroRNAs and autophagy in brain tumors
GBM is the most common as well as the most lethal pri-
mary tumor in the CNS [212, 213]. Nonetheless, all
GBMs are not uniform and can display fundamental het-
erogeneity and may contain small sub-populations of
cells, that have been called “glioma stem-like cells”
(GSCs). One study suggested that GSCs are mainly re-
sponsible for tumor initiation, specify the malignant
phenotype, cause therapy-resistance, and recurrence
[214]. Analysis of gene expression has categorized GSCs
extracted from patients into sub-types: mesenchymal
(MES); classical (CL); and proneural (PN) [215–217].
Among them, MES GSCs have been suggested to be the
most radiation-resistant and invasive cells [217]. The en-
hanced autophagic activities in the MES GSCs as com-
pared to the PN GSCs, has been implicated in the high
tumorigenicity and resistance to therapy [218].
MiR-93 is an important miRNA, which is highly
expressed in different human cancers, and functions as
one of the oncogenic miRNAs, through actuation of
PI3K-AKT signaling pathways [219, 220]. Nevertheless,
oncogenic effects of miR-93 has been considered to be
depended on the contexts. As an instace, miR-93 acts as
one of the tumour suppressors via suppressing parame-
ters in a TGF-β signaling pathway, and the genes re-
sponsible for cell stemness such as EZH1, SOX4, AKT3,
STAT3, JAK1, CDKN1A, and CCND2 [221, 222].
Huang and colleagues examined two clinically relevant
GBM subtypes, and found that miR-93 expression af-
fected the GSC phenotype, together with the response to
therapy, due to its effects on autophagy [223]. They also
showed that miR-93 modulated autophagy functions in
GSCs by synchronized suppression of several autophagy
modulators, such as SQSTM1/p62, ATG4B, ATG5 and
BECN1/beclin 1. Furthermore, two first-line GBM ther-
apies, Temozolomide (TMZ) and irradiation (IR), as well
as rapamycin (Rap) decreased the expression of miR-93,
which itself, triggered the autophagic cascades in the
GSCs. In fact, autophagy suppression using the ectopic
expression of miR-93, or mediated by autophagy
blockers, CQ and NSC (the ATG4B suppressor), in-
creased TMZ as well as IR activities against the GSCs.
The results suggested an important role for miR-93 in
autophagy regulation, and proposed a combination
therapeutic approach using autophagy suppression while
administering cytotoxic treatment [223].
It has been shown that miR-30a has suppressive effects
on autophagy, through direct targeting of beclin1 [224].
Xu and colleagues studied whether miR-30a enhanced
TMZ cytotoxicity against GBMU251 cells, and the
underlying mechanisms [225]. They found that TMZ
therapy blocked the proliferation of U251 cells, while in-
ducing apoptosis in a dose-dependent manner. More-
over, beclin1 and LC3-II expression levels, as well as the
LC3-II to LC3-I ratio were significantly enhanced in
TMZ-treated U251 cells in comparison to untreated
cells. These results suggested that TMZ therapy could
induce autophagy. Researchers found that TMZ therapy
resulted in a considerable reduction of miR-30a expres-
sion levels in U251 cells in a dose-dependent manner.
MiR-30a significantly suppressed autophagy induced by
TMZ, as confirmed by the reduced levels of beclin1 and
LC3-II, as well as lower ratio of LC3-II to the LC3-I, ac-
companied by elevated apoptosis as well as decreased
proliferation of TMZ-treated U251 cells. Overall, this
study showed that, miR-30a enhanced the TMZ chemo-
sensitivity of GBMU251 cells through direct suppression
of autophagy. Consequently, autophagy may be a target
for improving the treatment effects against TMZ-
resistant tumors [225].
Flavonoids (phenolic compounds derived from plants)
have a wide range of pharmacological properties includ-
ing antitumor activity. Studies have recently revealed the
ability of flavonoids to affect cancer cell metastasis,
angiogenesis, differentiation, proliferation, apoptosis, and
multi-drug resistance [226]. The anticancer impact of
luteolin (LUT), a naturally occurring flavonoid, includes
suppression of metastasis, angiogenesis, cell proliferation
and autophagy, as well as stimulation of apoptotic path-
ways [227]. During the passage through the intestinal
mucosa, some LUT molecules are probably converted to
glucuronides [228]. Due to its ability to cross the blood-
brain barrier, LUT could be considered an appropriate
molecule for the treatment of different brain tumors,
such as GBM [229].
Ray and Chakrabarti showed that a combination of
50 μM SIL (silibilin, a flavonolignan) and 20 μM LUT
synergistically inhibited the growth of T98G and
GBMU87MG cells, and the combination of these two
natural compounds was more effective than conven-
tional chemotherapy (100 μM TMZ or 10 μM BCNU)
[230]. The SIL and LUT combination suppressed GBM
cell growth via inducing apoptosis and inhibiting tumor
cell migration and invasion. Additionally, the SIL and
LUT combination repressed rapamycin (RAPA)-medi-
ated autophagy by PKCα suppression, and promoted
apoptosis through iNOS down-regulation. The combin-
ation also significantly enhanced the expression of the
tumor inhibitor miR-7-1-3p in GBM cells. It was also
shown that miR-7-1-3p over-expression increased the
antitumor activity of SIL and LUT in RAPA-pre-treated
T98G and U87MG cells. Consequently, these findings
indicated that miR-7-1-3p over-expression enhanced the
antitumor effects of SIL and LUT to induce apoptosis
and suppress autophagy in several human GBM-cells,
both in-vivo and in-vitro [230].
Under hypoxic conditions, autophagy can have a pro-
tective effect on cancer cells. Moreover, hypoxia affects
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Table 2 Selected autophagy-related miRNAs in brain tumors
Brain tumor miRNA Expression Effect (s)
on
autophagy
Target (s) Study outcome (s) Model Cell line Ref
GBM miR-
93
Up Inhibit
autophagy
BECN1/
Beclin 1,
ATG5,
ATG4B,
SQSTM1/p62
Autophagy inhibition increased antitumor
effects of Rap, IR, and TMZ on glioma stem-
like cells
In
vitro,
In vivo
U87 [237]
miR-
30a
Up Inhibit
autophagy
Beclin 1 MiR-30a over-expression increased the cyto-
toxicity of TMZ to U251 cells
In
vitro
U251 [225]
miR-
224-
3p
Up Inhibit
autophagy
ATG5 Mir-224-3p suppressed metastasis. It also
enhanced the chemo-sensitivity of LN229
cells in hypoxic conditions through autoph-
agy suppression
In
vitro,
In vivo
LN229 [238]
miR-
17
Up Inhibit
autophagy
ATG7 The activation of autophagy by anti-miR-17
led to a decrease of the threshold resistance
at temozolomide doses in T98G cells.
Modulation of miR-17 led to sensitization to
low dose ionizing radiation in U373-MG cells
In
vitro
T98G, U373-MG [115]
miR-
340
Up Inhibit
autophagy
XIAP, BMI1,
ROCK1
MiR-340 reduced cell growth, inhibited cell
motility, and regulated glioma development
In
vitro
U87MG, U251MG,
U373, A172, U118,
T98G, SHU-44
[239]
miR-
224-
3p
Up Inhibit
autophagy
ATG5, FIP200 MiR224-3p increased hypoxia-induced apop-
tosis, inhibited hypoxia-induced autophagy,
reduced cell proliferation in vitro, inhibited
tumorigenesis of GBM cells in vivo
In
vitro,
In vivo
U251, U87 [232]
miR-
517c
Up Inhibit
autophagy
Tp53 Mir-517c suppressed autophagy and
decreased tumor invasion
In
vitro,
In vivo
U251, U87 [240]
miR-7-
1-3p
Up Inhibit
autophagy
PKCa, mTOR,
SQSTM1,
p62, XIAP
MiR-7-1-3p over-expression potentiated sili-
binin & luteolin to induce apoptosis and in-
hibit autophagy
In
vitro,
in vivo
U87MG, T98G [230]
miR-
138
Up Inhibit
autophagy
LC3-II, BIM MiR-138/BIM axis regulated autophagy-
mediated resistance to TMZ
In
vitro,
In vivo
LN-18, LN-229, LN-
308, LN-319, LN-428,
D247MG, A172,
U87MG, T98G
[241]
miR-
155-
3p
Up Activate
autophagy
LC3B-II,
SQSTM1
MIR155-3p enhanced hypoxia-induced au-
tophagy through targeting the CREBRF-
CREB3-ATG5 pathways
In
vitro,
In vivo
U251, T98G [242]
miR-
30e
Up Inhibit
autophagy
Beclin-1 Combination of proanthocyanidin and miR-
30e suppressed sodium sulfite-induced
autophagy
In
vitro
GSC, SNB19 [243]
miR-
128
Up Activate
autophagy
mTOR,
RICTOR,
IGF1, PIK3R1
MiR-128 directly blocked mTOR pathway
and induced glioma cell death
In
vitro
Hs683, M059K,
U87MG
[244]
miR-
590-
3p
Up Activate
autophagy
LC3-II,
Beclin-1,
TMZ combined with endothelial-monocyte
actuating polypeptide II inhibited malignant
phenotype of GSCs through miR-590-3p/
MACC1 suppressing the PI3K/AKT/mTOR sig-
naling pathways
In
vitro,
In vivo
U87, U251 [245]
Scwannoma miR-
21
Up Inhibit
autophagy
LC3-II,
Beclin-1
Ailanthone-induced autophagy & apoptosis,
suppressed proliferation of vestibular
schwannoma cells
In
vitro
vestibular
schwannoma
[234]
miR-
210
Up Activate
autophagy
P62, elf4E Inhibition of miR-210 promoted tumor cell
apoptosis and cell cycle arrest, decreased
angiogenesis, and activated autophagy
In
vitro
RT4-D6P2T [246]
Medulloblastoma miR-
30a
Up Inhibit
autophagy
LC3B, Beclin-
1
Mir-30a inhibited tumorigenicity and growth
of medulloblastoma cell lines, and
suppressed autophagy
In
vitro,
In vivo
Daoy, D283, D425 [236]
Let-7f- Up Inhibit HMGB1 SPARC regulated cisplatin resistance by In D425 [247]
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protein stability, mRNA stability, and also mRNA tran-
scription. In addition, hypoxia causes a shift in expres-
sion levels of a particular class of miRNAs [231]. The
mechanisms of miRNA-associated hypoxia-induced au-
tophagy in GBM are not yet fully understood. A study
using miRNA microarray analysis in GBM cells, revealed
the differential expression of several miRNAs under hyp-
oxic condition [232]. It has also been reported that
miR224-3p could be implicated in the regulation of
hypoxia-mediated autophagy in GBM cells. The over-
expression of miR224-3p inhibited hypoxia-induced au-
tophagy, while its down-regulation promoted autophagy
under normoxic conditions. Moreover, one study [232]
reported that miR224-3p directly suppressed the expres-
sion of two autophagy-associated genes i.e., ATG5 &
FAK family interacting protein of 200 kDa (FIP200) and
therefore inhibited autophagy. Furthermore, miR224-3p
enhanced hypoxia-induced apoptosis and decreased cell
proliferation in vitro, and its over-expression inhibited
GBM tumorigenesis in vivo. These authors demon-
strated that miR224-3p is a new down-regulated miRNA
in hypoxia, and could be a significant autophagy regula-
tor by suppression of ATGs in GBM cells.
Vestibular schwannoma (VS) is a Schwann cell tumor
of the vestibular nerves, and comprises about 10% of
intracranial neoplasms [233]. VS occurs in both familial
(neurofibromatosis type 2, NF2) and sporadic forms,
both of which are related to defects in the NF2 gene
[233]. In one investigation, the antitumor effects of
ailanthone (AIL) (a quassinoid compound derived from
the traditional Chinese medicinal herb, Ailanthus altis-
sima) against VS was evaluated by Yang and colleagues
[234]. Different doses of AIL (0–1 μM) were used to
treat VS cells, and autophagy, apoptosis, cell viability
and proliferation were evaluated. After miRNA transfec-
tion, miR-21 expression was increased in VS cells. AIL
significantly decreased VS cell viability. In response to
0.6 μM AIL, p62 was down-regulated, beclin-1 and LC3-
II were accumulated, caspase 3 and caspase-9 were
cleaved, the rate of apoptotic cells was increased, and
the expression of cyclin D1 as well as the proportion of
BrdU+ cells were decreased. miR-21 was poorly
expressed in cells treated with AIL, and furthermore
AIL-mediated autophagy and apoptosis were reduced by
the over-expression of miR-21. Furthermore, AIL down-
regulated Raf and Ras, and also deactivated p70S6K,
mTOR, ERK and MEK, whereas the deactivation and
down-regulation of these mediators induced by AIL
were reversed by miR-21 over-expression. Consequently,
AIL suppressed the proliferation of VS cells and induced
autophagy and apoptosis. The anticancer properties of
AIL in VS cells were explained by miR-21 down-
regulation and consequent suppression of the mTOR
and Ras/Raf/MEK/ERK pathways [234].
Approximately, 30% of patients with medulloblastoma,
another malignant pediatric brain tumor [235], undergo
metastasis at an early stage, and therefore they have a
poor prognosis. If harsh cytotoxic therapy is adminis-
tered to children whose brain is still developing, the sur-
viving patients can suffer long-lasting developmental,
endocrine and neurocognitive deficits. Therefore, in
order to achieve a more effective treatment for medullo-
blastoma with fewer side effects, it is essential to dis-
cover more targeted therapeutic approaches based on
validated biological mechanisms. It is believed that, be-
cause the SHH and WNT developmental pathways are
involved, medulloblastoma could result from the deregu-
lated expansion of cells in the nervous system [235].
Moreover, one study carried out by Singh et al. found
low expression levels of miR-30a (which targets beclin1)
in the medulloblastoma cell lines, D425, D283, and Daoy.
Restoring the miR-30a expression level blocked tumori-
genicity, and reduced the clonogenic potential as well as
the proliferation of the medulloblastoma cells. It was pro-
posed that miR-30a down-regulates the expression of
beclin1, and suppresses autophagy in medulloblastoma
cell-lines, by LC3B down-regulation. This could be re-
versed by CQ therapy, which induces starvation-induced
autophagy. Therefore, miR-30a could be considered as a
treatment approach for medulloblastoma, via suppressing
autophagy, reversing the malignant phenotype, and redu-
cing survival of cancer cells [236].
Table 2 Selected autophagy-related miRNAs in brain tumors (Continued)
Brain tumor miRNA Expression Effect (s)
on
autophagy
Target (s) Study outcome (s) Model Cell line Ref
1 autophagy regulating the Let-7f-1 miRNA/HMGB1 axis vitro,
In vivo
UW228
Glioma miR-
193a-
5p
Up Activate
autophagy
LCII/LCI,
Beclin-1
CASC2 is down-regulated in glioma, leading
to enhanced levels of miR-193a-5p and de-
creased expression of mTOR, resulting in in-
creased autophagy
In
vitro
U257, U87 [248]
Astrocytoma miR-
224-
3p
Up Inhibit
autophagy
ATG5 HIF-1α/miR-224-3p/ATG5 axis influenced
chemosensitivity and cell mobility through
modulating hypoxia-mediated autophagy
In
vitro,
In vivo
U-251MG [245]
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Table 2 lists some of the various miRNAs that have
been associated with autophagy in brain tumors.
Conclusion
Due to the generally poor survival of patients diagnosed
with malignant brain tumors (especially GBM), it is ne-
cessary to discover novel therapeutic strategies with
fewer side effects. According to mounting evidence, dis-
turbed autophagy critically contributes to the pathogen-
esis as well as progression of brain tumors. Therefore,
new rationally designed drugs are needed, that should be
soundly based on the underlying mechanisms of autoph-
agy. Recent data shows that miRNAs can regulate and
influence autophagy through different pathways. There-
fore, miRNAs such as miR-30a, could be considered as a
new therapeutic approach for the therapy of brain tu-
mors, via suppressing autophagy, which has been shown
to play a role on the malignant phenotype, survival and
growth of cancer cells. The present review has summa-
rized studies related to this concept, but it is obvious
that there is still a long way to go before miRNA-based
drugs could be used for brain tumor treatment. In order
to find novel potential drugs for brain tumors, further
attention should be focused on the regulatory properties
of different miRNAs in the autophagy cascade. To reach
this goal, more experimental studies must be conducted
to clarify the underlying molecular mechanisms, and
then clinical trials could be warranted to prove the ef-
fectiveness and safety of therapies based on miRNAs.
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